Enveloped virus-like particle platforms: vaccines of the future?

Pitoiset, Fabien; Vazquez, Thomas; Bellier, Bertrand

doi:10.1586/14760584.2015.1046440

Cited by 35 publications

(34 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…By displaying native virus proteins, VLPs can stimulate a high and protective immune response presenting an effective and safer alternative compared to killed or attenuated virus, due to the lack of viral genetic material . In fact, there are already VLP vaccines in the market for hepatitis B virus, hepatitis E virus, and human papillomavirus . Influenza VLPs can be produced using the insect cells/baculovirus expression vector system as efficiently as egg or mammalian cell‐based technologies .…”

Section: Introductionmentioning

confidence: 99%

“…In fact, there are already VLP vaccines in the market for hepatitis B virus, hepatitis E virus, and human papillomavirus . Influenza VLPs can be produced using the insect cells/baculovirus expression vector system as efficiently as egg or mammalian cell‐based technologies . Moreover, the structural flexibility of VLPs allows the display of multiple hemagglutinin (HA) and/or neuraminidase proteins in their surface from different strains.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Membrane‐Based Approach for the Downstream Processing of Influenza Virus‐Like Particles

Carvalho

Silva

Moleirinho

et al. 2019

Biotechnology Journal

View full text Add to dashboard Cite

Currently, marketed influenza vaccines are only efficient against homologous viruses, thus requiring a seasonal update based on circulating subtypes. This constant reformulation adds several challenges to manufacturing, particularly in purification due to the variation of the physicochemical properties of the vaccine product. A universal platform approach capable of handling such variation is therefore of utmost importance. In this work, a filtration‐based approach is explored to purify influenza virus‐like particles. Switching from adsorptive separation to size‐based purification allows overcoming the differences in retention observed for different influenza strains. The proposed process employs a cascade of ultrafiltration and diafiltration steps, followed by a sterile filtration step. Different process parameters are assessed in terms of product recovery and impurities’ removal. Membrane chemistry, pore size, operation modes, critical flux, transmembrane pressure, and permeate control strategies are evaluated. After membrane selection and parameter optimization, concentration factors and diafiltration volumes are also defined. By optimizing the filtration mode of operation, it is possible to achieve product recoveries of approximately 80%. Overall, the process time is decreased by 30%, its scalability is improved, and the costs are reduced due to the removal of chromatography and associated buffer consumptions, cleaning, and its validation steps.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Membrane‐Based Approach for the Downstream Processing of Influenza Virus‐Like Particles

Carvalho

Silva

Moleirinho

et al. 2019

Biotechnology Journal

View full text Add to dashboard Cite

show abstract

“…VLPs lack viral genome, and mimic the key structural and functional features of viruses, representing a safe and effective vaccine platform [13,14]. In addition, VLPs can be produced in insect cell expression systems, where foreign antigens can be displayed.…”

Section: Discussionmentioning

confidence: 99%

Virus-Like Nanoparticle Vaccine Confers Protection against Toxoplasma gondii

Lee

Kim

et al. 2016

PLoS ONE

View full text Add to dashboard Cite

The inner membrane complex (IMC) of Toxoplasma gondii as a peripheral membrane system has unique and critical roles in parasite replication, motility and invasion. Disruption of IMC sub-compartment protein produces a severe defect in T. gondii endodyogeny, the form of internal cell budding. In this study, we generated T. gondii virus-like particle particles (VLPs) containing proteins derived from IMC, and investigated their efficacy as a vaccine in mice. VLP vaccination induced Toxoplasma gondii-specific total IgG, IgG1 and IgG2a antibody responses in the sera and IgA antibody responses in the feces. Upon challenge infection with a lethal dose of T. gondii (ME49), all vaccinated mice survived, whereas all naïve control mice died. Vaccinated mice showed significantly reduced cyst load and cyst size in the brain. VLP vaccination also induced IgA and IgG antibody responses in feces and intestines, and antibody-secreting plasma cells, mixed Th1/Th2 cytokines and CD4+/CD8+ T cells from spleen. Taken together, these results indicate that non-replicating VLPs containing inner membrane complex of T. gondii represent a promising strategy for the development of a safe and effective vaccine to control the spread of Toxoplasma gondii infection.

show abstract

“…Virus-like particles (VLPs) are self-assembly systems that spontaneously form virus-shaped particles following expression of one or more viral proteins (23). RTS,S, for example, is a VLP based on the hepatitis B surface antigen (24). VLPs are able to induce strong B-cell responses in the absence of adjuvants by efficiently cross-linking specific receptors on B cells (25).…”

Section: Introductionmentioning

confidence: 99%

Evaluation of Plasmodium vivax Cell-Traversal Protein for Ookinetes and Sporozoites as a Preerythrocytic P. vivax Vaccine

Alves

Salman

Leoratti

et al. 2017

Clin Vaccine Immunol

View full text Add to dashboard Cite

Four different vaccine platforms, each targeting the human malaria parasite Plasmodium vivax cell-traversal protein for ookinetes and sporozoites (PvCelTOS), were generated and assessed for protective efficacy. These platforms consisted of a recombinant chimpanzee adenoviral vector 63 (ChAd63) expressing PvCelTOS (Ad), a recombinant modified vaccinia virus Ankara expressing PvCelTOS (MVA), PvCelTOS conjugated to bacteriophage Qβ virus-like particles (VLPs), and a recombinant PvCelTOS protein expressed in eukaryotic HEK293T cells (protein). Inbred BALB/c mice and outbred CD-1 mice were immunized using the following prime-boost regimens: Ad-MVA, Ad-VLPs, and Ad-protein. Protective efficacy against sporozoite challenge was assessed after immunization using a novel chimeric rodent Plasmodium berghei parasite (Pb-PvCelTOS). This chimeric parasite expresses P. vivax CelTOS in place of the endogenous P. berghei CelTOS and produces fully infectious sporozoites. A single Ad immunization in BALB/c and CD-1 mice induced anti-PvCelTOS antibodies which were boosted efficiently using MVA, VLP, or protein immunization. PvCelTOS-specific gamma interferon- and tumor necrosis factor alpha-producing CD8+ T cells were induced at high frequencies by all prime-boost regimens in BALB/c mice but not in CD-1 mice; in CD-1 mice, they were only marginally increased after boosting with MVA. Despite the induction of anti-PvCelTOS antibodies and PvCelTOS-specific CD8+ T-cell responses, only low levels of protective efficacy against challenge with Pb-PvCelTOS sporozoites were obtained using any immunization strategy. In BALB/c mice, no immunization regimens provided significant protection against a Pb-PvCelTOS chimeric sporozoite challenge. In CD-1 mice, modest protective efficacy against challenge with chimeric P. berghei sporozoites expressing either PvCelTOS or P. falciparum CelTOS was observed using the Ad-protein vaccination regimen.

show abstract

Enveloped virus-like particle platforms: vaccines of the future?

Cited by 35 publications

References 17 publications

Membrane‐Based Approach for the Downstream Processing of Influenza Virus‐Like Particles

Membrane‐Based Approach for the Downstream Processing of Influenza Virus‐Like Particles

Virus-Like Nanoparticle Vaccine Confers Protection against Toxoplasma gondii

Evaluation of Plasmodium vivax Cell-Traversal Protein for Ookinetes and Sporozoites as a Preerythrocytic P. vivax Vaccine

Contact Info

Product

Resources

About